Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IN10018 + RNK08954 in KRAS G12D-mutant advanced solid tumors
CTR20254790Phase 2Active
- Sponsor
- InxMed
- Start
- Jan 2026
- Modality
- Small Molecules, PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ifebemtinib, RNK08954 in pancreatic adenocarcinoma (PDAC), non-small cell lung cancer (NSCLC), colorectal cancer (CRC), Nonhematologic neoplasms, sponsored by InxMed. Started Jan 2026; status: active.
02
Drugs
ifebemtinibRNK08954
03
Conditions
pancreatic adenocarcinoma (PDAC)non-small cell lung cancer (NSCLC)colorectal cancer (CRC)Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20254790.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254790.